PR Newswire News
- 16:13:00
- Xinhua Silk Road: Annual report on image of Suzhou city released to better tell Suzhou stories during 2021 AI Expo Thu.
- 08:00:00
- Innovent Releases Interim Analysis Results of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma in the Phase 3 ORIENT-15 Study at ESMO Congress 2021
- 08:00:00
- Innovent Releases Interim Analysis Results of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in the Phase 3 ORIENT-16 Study at ESMO Congress 2021
- 04:53:00
- SARS-CoV-2, Influenza A inactivated by zinc-embedded nylon fabric
2021-09-18
- 22:05:00
- Zoomlion Breaks Yet Another Record for High-End Manufacturing, Exports China's Largest Tonnage Crawler Crane
- 21:28:00
- ZTE wins largest share in bid section 4 of China Mobile's high-end router centralized procurement
- 21:19:00
- Hysan Development Acquires Premium Commercial Project in Jing'an District for RMB3.5 billion
- 20:40:00
- #WeToo launches movement to bring leading businesses and individuals into the fight against child abuse
- 20:00:00
- The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint
- 20:00:00
- InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CD20xCD3 Bispecific Antibody CM355
- 19:00:00
- Global Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 7, 2021
- 15:26:00
- Right Issue to Develop Ultra-Micro Ecosystem, A New Source of Growth Amidst the Pandemic
- 13:24:00
- The Way to Best LCOE (IV)
- 09:05:00
- "Dubbing Academy" Completed Successfully Helping Youths in Realising Dreams
- 08:36:00
- Red ginseng selected as the most popular Chuseok (Korean Thanksgiving day) gift in Korea
- 08:00:00
- Innovent Releases Phase 2 Results of Pemigatinib in Chinese Patients with Advanced Cholangiocarcinoma at ESMO Congress 2021
- 08:00:00
- CStone will present registrational clinical study data of Sugemalimab in patients with stage III non-small cell lung cancer in an oral presentation at ESMO Congress 2021
- 06:30:00
- Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases
- 05:37:00
- Nils Andersen-Röed joins Binance from Europol to further strengthen investigations and audit team
- 03:59:00
- PharmaZell and Novasep enter into exclusive negotiations in new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
2021-09-17
